Corporate Profile
Alpine is a clinical-stage specialty pharmaceutical company focused on discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune/inflammatory diseases. Our proprietary Variant Immunoglobulin Domain™ (“vIgD™”) and Variant Tumor Necrosis Factor Domain™ (“vTD™”) scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins. Our platform creates molecules which can be produced in multiple formats, including standard Fc fusion proteins, localized Fc fusion proteins, and monoclonal antibody fusion proteins as well as formulated as a Transmembrane Immunomodulatory Protein (“TIP™”) or as a Secreted Immunomodulatory Protein (“SIP™”).
